CCAD or eCRS: Defining Eosinophilic Subpopulations in Chronic Rhinosinusitis
- PMID: 36740860
- PMCID: PMC10273859
- DOI: 10.1177/19458924231155012
CCAD or eCRS: Defining Eosinophilic Subpopulations in Chronic Rhinosinusitis
Abstract
Background: Central compartment atopic disease (CCAD) and eosinophilic chronic rhinosinusitis (eCRS) are two clinical phenotypes of primary diffuse type 2 chronic rhinosinusitis (CRS) defined in the European Position Paper on Rhinosinusitis 2020 classification. Currently, the distinction between these subtypes relies on phenotypic features alone.
Objective: This study aimed to investigate whether eosinophil activation differed between CCAD and eCRS.
Methods: A cross-sectional study was conducted of adult patients presenting with CCAD and eCRS who had undergone functional endoscopic sinus surgery. Routine pathology results were obtained from clinical records. Eosinophils were counted on haematoxylin and eosin-stained formalin-fixed paraffin-embedded sinonasal tissue. Eotaxin-3, eosinophil peroxidase and immunoglobulin E levels were assessed using immunohistochemistry.
Results: 38 participants were included (51.7 ± 15.6 years, 47.4% female), of whom 36.8% were diagnosed with CCAD and 63.2% with eCRS. The eCRS group was characterised by older age (55.8 ± 16.3 vs 44.5 ± 11.8 years, p = 0.029), and on histology exhibited a higher degree of tissue inflammation (τb = 0.409, p = 0.011), greater proportion of patients with >100 eosinophils/high power field (87.5% vs 50%, p = 0.011), and higher absolute tissue eosinophil count (2141 ± 1947 vs 746 ± 519 cells/mm2, p = 0.013). Eotaxin-3 scores were higher in the eCRS group (5.00[5.00-6.00] vs 6.00[6.00-6.75], p = 0.015). Other outcomes were similar.
Conclusions: Eosinophil and eotaxin-3 levels were elevated in eCRS compared with CCAD, suggesting a greater degree of eosinophil stimulation and chemotaxis. Patients with CCAD were younger. Future investigation and biomarkers may better distinguish CRS subpopulations.
Keywords: CCAD; Th2; allergic rhinitis; allergy; central compartment; chronic rhinosinusitis; endotype; eosinophils; inhalant allergy; middle turbinate oedema; phenotype; polyps; type 2.
Conflict of interest statement
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Richard J Harvey is a consultant/advisory board with Medtronic, Novartis, Glaxo-Smith-Kline and Meda Pharmaceuticals. He has been on the speakers' bureau for Glaxo-Smith-Kline, AstraZeneca, Meda Pharmaceuticals and Seqiris. Janet Rimmer has honoraria with Sanofi Aventis, Novartis, Mundipharma, BioCSL and Stallergenes. Larry Kalish is on the speakers' bureau for Care Pharmaceuticals and Mylan Pharmaceuticals. All other authors have no financial disclosures or conflicts of interest.
Figures
References
-
- Fokkens WJ, Lund VJ, Hopkins C, et al.European Position paper on rhinosinusitis and nasal polyps. Rhinology. 2020;58(Supplement 29):1–464. - PubMed
-
- DelGaudio JM, Loftus PA, Hamizan AW, et al.Central compartment atopic disease. Am J Rhinol Allergy. 2017;31(4):228–234. - PubMed
-
- Hamizan AW, Loftus PA, Alvarado R, et al.Allergic phenotype of chronic rhinosinusitis based on radiologic pattern of disease. Laryngoscope. 2018;128(9):2015–2021. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
